Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Dermatitis atopic · Cancer

Sanofi-Aventis U.S

Sanofi-aventis Healthcare Pty Ltd

Sanofi-Aventis U.S drug portfolio — 148 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Website Investor relations
Bridgewater, USA HQ
177 Employees
TGA registrant Type
Company details
Status
Public
HQ
Bridgewater, USA
Employees
177
Programs
117
Drugs
148
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Drug Pipeline

Sanofi-Aventis U.S pipeline

Portfolio lens on 148 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Sanofi-Aventis U.S drug portfolio — 148 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

148 compounds

  2. abemaciclib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.

    Target
    Cyclin-dependent kinase 4
    Mechanism
    Cyclin-dependent kinase 6 inhibitor

  3. afamelanotide

    Dermatologicals (D02)

    US regulatory status: approved. Molecular target: Melanocyte-stimulating hormone receptor.

    Target
    Melanocyte-stimulating hormone receptor
    Mechanism
    Melanocortin receptor 1 agonist

  4. agalsidase alfa

    Alimentary tract and metabolism (A16)

    Alimentary tract and metabolism (A16) compound in Sanofi-Aventis U.S's portfolio. Molecular target: Globotriosylceramide.

    Target
    Globotriosylceramide
    Mechanism
    Globotriosylceramide hydrolytic enzyme

  5. agalsidase beta

    Alimentary tract and metabolism (A16)

    US regulatory status: approved. Molecular target: Globotriosylceramide.

    Target
    Globotriosylceramide
    Mechanism
    Globotriosylceramide hydrolytic enzyme

  6. albuterol

    US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.

    Target
    Beta-2 adrenergic receptor
    Mechanism
    Beta-2 adrenergic receptor agonist

  7. albuterol sulfate

    US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.

    Target
    Beta-2 adrenergic receptor
    Mechanism
    Beta-2 adrenergic receptor agonist

  8. alemtuzumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: CAMPATH-1 antigen.

    Target
    CAMPATH-1 antigen
    Mechanism
    CAMPATH-1 antigen inhibitor

  9. alfuzosin

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records. Mechanism: Adrenergic receptor alpha-1 agonist.

    Mechanism
    Adrenergic receptor alpha-1 agonist

  10. alglucosidase

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records. Molecular target: Starch.

    Target
    Starch
    Mechanism
    Starch hydrolytic enzyme

  11. alglucosidase alfa

    Alimentary tract and metabolism (A16)

    US regulatory status: approved. Molecular target: Starch.

    Target
    Starch
    Mechanism
    Starch hydrolytic enzyme

  12. alpha1-proteinase inhibitor (human)

    Blood and blood forming organs (B02)

    Blood and blood forming organs (B02) compound in Sanofi-Aventis U.S's portfolio. Molecular target: Neutrophil elastase.

    Target
    Neutrophil elastase
    Mechanism
    Leukocyte elastase inhibitor

  13. antagonist

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  14. anti-

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  15. antibody

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  16. avalglucosidase alfa

    Alimentary tract and metabolism (A16)

    Alimentary tract and metabolism (A16) compound in Sanofi-Aventis U.S's portfolio. Molecular target: Glycogen.

    Target
    Glycogen
    Mechanism
    Glycogen hydrolytic enzyme

  17. beclometasone

    Respiratory system (R03)

    Respiratory system (R03) compound in Sanofi-Aventis U.S's portfolio.

  18. belumosudil

    Antineoplastic and immunomodulating agents (L04)

    Antineoplastic and immunomodulating agents (L04) compound in Sanofi-Aventis U.S's portfolio. Molecular target: Rho-associated protein kinase 2.

    Target
    Rho-associated protein kinase 2
    Mechanism
    Rho-associated protein kinase inhibitor

  19. bevacizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.

    Target
    Vascular endothelial growth factor A, long form
    Mechanism
    Vascular endothelial growth factor A inhibitor

  20. bisacodyl

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  21. bortezomib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: 26S proteasome.

    Target
    26S proteasome
    Mechanism
    26S proteosome inhibitor

  22. budesonide

    Alimentary tract and metabolism (A07)

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  23. canakinumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Interleukin-1 beta.

    Target
    Interleukin-1 beta
    Mechanism
    Interleukin-1 beta inhibitor

  24. caplacizumab

    Blood and blood forming organs (B01)

    Blood and blood forming organs (B01) compound in Sanofi-Aventis U.S's portfolio. Molecular target: von Willebrand factor.

    Target
    von Willebrand factor
    Mechanism
    von Willebrand factor inhibitor

  25. capsule

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  26. capsules

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  27. carboplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  28. carfilzomib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: 26S proteasome.

    Target
    26S proteasome
    Mechanism
    26S proteosome inhibitor

  29. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  30. cemiplimab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Sanofi-Aventis U.S's portfolio. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  31. cend-

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  32. cetirizine

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.

    Mechanism
    Histamine H1 receptor antagonist

  33. cetuximab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Epidermal growth factor receptor.

    Target
    Epidermal growth factor receptor
    Mechanism
    Epidermal growth factor receptor erbB1 inhibitor

  34. chloride

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  35. chlorpheniramine

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.

    Mechanism
    Histamine H1 receptor antagonist

  36. cisplatin

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    DNA inhibitor

  37. colestyramine

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records. Molecular target: Bile acids.

    Target
    Bile acids
    Mechanism
    Bile acids sequestering agent

  39. control

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  40. covid-19 vaccine (inactivated, adjuvanted, adsorbed)

    Antiinfectives for systemic use (J07)

    Antiinfectives for systemic use (J07) compound in Sanofi-Aventis U.S's portfolio. Mechanism: Biological vaccine - induces immune response.

    Mechanism
    Biological vaccine - induces immune response

  41. dendritic

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  42. desonide

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  43. dexamethasone phosphate

    Systemic hormonal preparations (H02)

    Systemic hormonal preparations (H02) compound in Sanofi-Aventis U.S's portfolio.

  44. dexamethasone sodium phosphate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  45. diethylpropion hydrochloride

    US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.

    Target
    Sodium-dependent dopamine transporter
    Mechanism
    Norepinephrine transporter inhibitor

  46. diltiazem

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records. Mechanism: Voltage-gated L-type calcium channel blocker.

    Mechanism
    Voltage-gated L-type calcium channel blocker

  47. diphenhydramine

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.

    Mechanism
    Histamine H1 receptor antagonist

  48. diphenhydramine hydrochloride

    US regulatory status: approved. Molecular target: Histamine H1 receptor.

    Target
    Histamine H1 receptor
    Mechanism
    Histamine H1 receptor antagonist

  52. docetaxel

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  53. dose

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  54. dupilumab

    Dermatologicals (D11)

    US regulatory status: approved. Molecular target: Interleukin-4 receptor subunit alpha.

    Target
    Interleukin-4 receptor subunit alpha
    Mechanism
    Interleukin-4 receptor subunit alpha antagonist

  55. emicizumab

    Blood and blood forming organs (B02)

    US regulatory status: approved. Molecular target: Coagulation factor IX and X.

    Target
    Coagulation factor IX and X
    Mechanism
    Coagulation factor IX and X other

  56. enoxaparin sodium

    Blood and blood forming organs (B01)

    US regulatory status: approved. Molecular target: Antithrombin-III.

    Target
    Antithrombin-III
    Mechanism
    Antithrombin-III activator

  57. estradiol

    US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor alpha agonist

  58. estropipate

    US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor alpha agonist

  59. fexofenadine

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.

    Mechanism
    Histamine H1 receptor antagonist

  61. fludarabine

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  62. fluticasone

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  63. formulation

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  64. gadobutrol

    US regulatory status: approved. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  65. glargine

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  66. glibenclamide

    Alimentary tract and metabolism (A10)

    Alimentary tract and metabolism (A10) compound in Sanofi-Aventis U.S's portfolio. Molecular target: Sulfonylurea receptor 1, Kir6.2.

    Target
    Sulfonylurea receptor 1, Kir6.2
    Mechanism
    Sulfonylurea receptor 1, Kir6.2 blocker

  67. glyceryl trinitrate

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records. Molecular target: Soluble guanylate cyclase.

    Target
    Soluble guanylate cyclase
    Mechanism
    Soluble guanylate cyclase activator

  68. group

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  69. haemophilus

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  70. hema-

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  71. high-dose

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  72. human heterologous liver cells

    Alimentary tract and metabolism (A16)

    Alimentary tract and metabolism (A16) compound in Sanofi-Aventis U.S's portfolio.

  73. hydroxychloroquine

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records. Mechanism: Toll-like receptor 7 antagonist.

    Mechanism
    Toll-like receptor 7 antagonist

  74. hyoscine butylbromide

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  75. hypromellose

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  76. imiglucerase

    Alimentary tract and metabolism (A16)

    US regulatory status: approved. Molecular target: Glucocerebroside.

    Target
    Glucocerebroside
    Mechanism
    Glucocerebroside hydrolytic enzyme

  77. inactivated

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  79. infusion

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  80. injection

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  81. insulin

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  82. insulin glargine

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  83. insulin glulisine

    Alimentary tract and metabolism (A10)

    Alimentary tract and metabolism (A10) compound in Sanofi-Aventis U.S's portfolio. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  84. isatuximab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Sanofi-Aventis U.S's portfolio. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.

    Target
    ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
    Mechanism
    Lymphocyte differentiation antigen CD38 inhibitor

  85. lenalidomide

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.

    Target
    CRL4(CRBN) E3 ubiquitin ligase
    Mechanism
    CRL4(CRBN) E3 ubiquitin ligase inhibitor

  86. levonorgestrel

    US regulatory status: approved. Molecular target: Progesterone receptor.

    Target
    Progesterone receptor
    Mechanism
    Progesterone receptor agonist

  87. loratadine

    US regulatory status: approved. Molecular target: Histamine H1 receptor.

    Target
    Histamine H1 receptor
    Mechanism
    Histamine H1 receptor antagonist

  88. low-dose

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  89. maintenance

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  90. matching

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  91. meningococcal

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  94. methotrexate

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Dihydrofolate reductase inhibitor

  95. methylprednisolone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  96. migalastat

    Alimentary tract and metabolism (A16)

    Alimentary tract and metabolism (A16) compound in Sanofi-Aventis U.S's portfolio. Molecular target: Alpha-galactosidase A.

    Target
    Alpha-galactosidase A
    Mechanism
    Alpha-galactosidase A stabiliser

  97. mometasone

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  98. monoclonal

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  99. montelukast

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records. Mechanism: Cysteinyl leukotriene receptor 1 antagonist.

    Mechanism
    Cysteinyl leukotriene receptor 1 antagonist

  100. nabilone

    US regulatory status: approved. Molecular target: Cannabinoid receptor 1.

    Target
    Cannabinoid receptor 1
    Mechanism
    Cannabinoid CB1 receptor agonist

  101. norgestrel

    US regulatory status: approved. Molecular target: Progesterone receptor.

    Target
    Progesterone receptor
    Mechanism
    Progesterone receptor agonist

  102. oxybutynin

    Genito-urinary system and sex hormones (G04)

    US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M2.

    Target
    Muscarinic acetylcholine receptor M2
    Mechanism
    Muscarinic acetylcholine receptor M2 antagonist

  103. palbociclib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: CDK6/cyclin D1.

    Target
    CDK6/cyclin D1
    Mechanism
    Cyclin-dependent kinase 4/cyclin D1 inhibitor

  104. paracetamol

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records. Molecular target: Fatty-acid amide hydrolase 1.

    Target
    Fatty-acid amide hydrolase 1
    Mechanism
    Anandamide amidohydrolase inhibitor

  105. pembrolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  106. pemetrexed sodium

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  107. pimecrolimus

    US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.

    Target
    Peptidyl-prolyl cis-trans isomerase FKBP1A
    Mechanism
    FK506-binding protein 1A inhibitor

  108. placebo

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  109. pneumococcal

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  113. polysaccharide

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  114. pomalidomide

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.

    Target
    CRL4(CRBN) E3 ubiquitin ligase
    Mechanism
    CRL4(CRBN) E3 ubiquitin ligase inhibitor

  115. powder

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  116. prednisolone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  117. prednisone

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  118. promethazine hydrochloride

    US regulatory status: approved. Molecular target: Histamine H1 receptor.

    Target
    Histamine H1 receptor
    Mechanism
    Histamine H1 receptor antagonist

  119. ramipril + felodipine

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  120. riluzole

    Nervous system (N07)

    US regulatory status: approved. Molecular target: Sodium channel alpha subunit.

    Target
    Sodium channel alpha subunit
    Mechanism
    Sodium channel alpha subunit blocker

  121. rilzabrutinib

    Nervous system (NOT)

    US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.

    Target
    Tyrosine-protein kinase BTK
    Mechanism
    Tyrosine-protein kinase BTK inhibitor

  122. rotateq

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records. Mechanism: Biological vaccine - induces immune response.

    Mechanism
    Biological vaccine - induces immune response

  123. rotavirus vaccine

    Antiinfectives for systemic use (J07)

    Antiinfectives for systemic use (J07) compound in Sanofi-Aventis U.S's portfolio. Mechanism: Biological vaccine - induces immune response.

    Mechanism
    Biological vaccine - induces immune response

  124. rotavirus vaccine, live

    Antiinfectives for systemic use (J07)

    Antiinfectives for systemic use (J07) compound in Sanofi-Aventis U.S's portfolio. Mechanism: Biological vaccine - induces immune response.

    Mechanism
    Biological vaccine - induces immune response

  125. salmeterol

    Respiratory system (R03)

    Respiratory system (R03) compound in Sanofi-Aventis U.S's portfolio. Mechanism: Beta-2 adrenergic receptor agonist.

    Mechanism
    Beta-2 adrenergic receptor agonist

  126. sar443122

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  127. sarilumab

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Interleukin-6 receptor subunit alpha.

    Target
    Interleukin-6 receptor subunit alpha
    Mechanism
    Interleukin-6 receptor alpha subunit antagonist

  128. selenium sulfide

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  129. sevelamer

    Various (V03)

    Various (V03) compound in Sanofi-Aventis U.S's portfolio.

  131. sodium polystyrene sulfonate

    US regulatory status: approved. Molecular target: Potassium.

    Target
    Potassium
    Mechanism
    Potassium sequestering agent

  132. solution

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  133. solvent

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  134. spesolimab

    Antineoplastic and immunomodulating agents (L04)

    Antineoplastic and immunomodulating agents (L04) compound in Sanofi-Aventis U.S's portfolio. Molecular target: IL36 receptor.

    Target
    IL36 receptor
    Mechanism
    IL36 receptor antagonist

  135. standard

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  136. subcutaneous

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  137. suspension

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  138. tablet

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  139. tablets

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  140. tacrolimus

    Dermatologicals (D11)

    US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.

    Target
    Peptidyl-prolyl cis-trans isomerase FKBP1A
    Mechanism
    FK506-binding protein 1A inhibitor

  141. teplizumab

    Alimentary tract and metabolism (A10)

    Alimentary tract and metabolism (A10) compound in Sanofi-Aventis U.S's portfolio. Molecular target: T-cell surface glycoprotein CD3 epsilon chain.

    Target
    T-cell surface glycoprotein CD3 epsilon chain
    Mechanism
    T-cell surface glycoprotein CD3 epsilon chain other

  142. teriflunomide

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Dihydroorotate dehydrogenase (quinone), mitochondrial.

    Target
    Dihydroorotate dehydrogenase (quinone), mitochondrial
    Mechanism
    Dihydroorotate dehydrogenase inhibitor

  143. therapy

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  144. thyrotropin alfa

    Systemic hormonal preparations (H01)

    US regulatory status: approved. Molecular target: Thyrotropin receptor.

    Target
    Thyrotropin receptor
    Mechanism
    Thyroid stimulating hormone receptor agonist

  145. tolebrutinib

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records. Molecular target: Tyrosine-protein kinase BTK.

    Target
    Tyrosine-protein kinase BTK
    Mechanism
    Tyrosine-protein kinase BTK inhibitor

  146. treatment

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  147. vaccine

    Development asset linked to Sanofi-Aventis U.S in public FDA and regional records.

  148. vigabatrin

    Nervous system (N03)

    US regulatory status: approved. Molecular target: 4-aminobutyrate aminotransferase, mitochondrial.

    Target
    4-aminobutyrate aminotransferase, mitochondrial
    Mechanism
    Gamma-amino-N-butyrate transaminase inhibitor

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.